Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
- FDA Approves First Extended-Release, Injectable Drug Regimen ... - HIV.gov
[Yesterday] the U.S. Food and Drug Administration approved...
- FDA Approves First Extended-Release, Injectable Drug Regimen ... - HIV.gov
Apretude is given first as two initiation injections administered one month apart, and then every two months thereafter. Patients can either start their treatment with Apretude or take oral...
23 Δεκ 2021 · Apretude, a new drug approved by the FDA this week, is an injection that has proven to be significantly more effective at reducing the risk of sexually-acquired HIV.
18 Νοε 2021 · Thousands of people with HIV will now be offered a new long-acting injection to manage their condition if they would prefer to stop taking daily pills. Charities have welcomed the approval of the...
22 Αυγ 2023 · Descovy, approved to prevent H.I.V. in men and transgender women, is thought to be safer than Truvada. And cabotegravir, a bimonthly injection, is an alternative for people who are unable...
22 Ιαν 2021 · [Yesterday] the U.S. Food and Drug Administration approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral ...
23 Δεκ 2021 · In clinical trials, cabotegravir proved to be 69% more effective than oral PrEP in preventing HIV among men who have sex with men. And it was 90% more effective than conventional PrEP among...
